English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Clinical assessment of MPV is ongoing. Currently, three lines of evidence suggest that it is potentially a clinically useful biomarker for risk stratification of patients who may develop coronary artery disease after PCI. First, several studies have addressed the frequencies of impaired reperfusion, left ventricular systolic dysfunction, and mortality in patients with acute myocardial infarction (AMI) who have undergone primary PCI or thrombolysis. 2,3 Second, some studies have shown that MPV is a useful predictive marker of shortand long-term clinical outcomes in unselected PCI cohorts, regardless of whether the patients had undergone elective or primary PCI. 4

Mean platelet volume as a biomarker of the risk and prognosis of coronary artery disease